Profile data is unavailable for this security.
About the company
OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
- Revenue in EUR (TTM)2.23m
- Net income in EUR-23.00m
- Incorporated2004
- Employees55.00
- LocationOSE Immunotherapeutics SA22, boulevard Benoni GoullinNANTES 44200FranceFRA
- Phone+33 228291010
- Fax+33 141219107
- Websitehttps://ose-immuno.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventiva SA | 17.48m | -110.43m | 98.66m | 112.00 | -- | -- | -- | 5.64 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Maat Pharma SA | 2.23m | -19.72m | 101.60m | 50.00 | -- | 4.14 | -- | 45.60 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Eurofins-Cerep SA | 44.07m | 7.64m | 107.94m | 228.00 | 14.13 | 1.67 | 11.23 | 2.45 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Transgene SA | 7.63m | -22.33m | 135.20m | 158.00 | -- | 6.58 | -- | 17.71 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Cellectis SA | 17.59m | -88.47m | 149.23m | 235.00 | -- | 1.12 | -- | 8.48 | -1.39 | -1.11 | 0.2345 | 1.86 | 0.0619 | -- | 3.86 | 74,861.99 | -31.74 | -24.08 | -46.51 | -30.69 | -- | -64.64 | -513.02 | -308.24 | -- | -6.95 | 0.4142 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Innate Pharma SA | 24.85m | -34.05m | 165.98m | 168.00 | -- | 5.76 | -- | 6.68 | -0.4215 | -0.4215 | 0.3078 | 0.3557 | 0.1418 | -- | 14.93 | 138,826.80 | -19.43 | -8.83 | -24.80 | -12.11 | 88.00 | 93.17 | -137.03 | -55.55 | -- | -- | 0.7527 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 167.34m | 55.00 | -- | 7.21 | -- | 75.14 | -1.18 | -1.18 | 0.1138 | 1.06 | 0.0256 | -- | 3.22 | 40,490.91 | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -55.59 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Genfit SA | 38.18m | -28.89m | 195.26m | 159.00 | -- | 2.87 | -- | 5.11 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Nanobiotix SA | 36.22m | -33.47m | 218.98m | 102.00 | -- | -- | -- | 6.05 | -0.763 | -0.763 | 0.8429 | -0.4594 | 0.57 | -- | 17.20 | 355,107.80 | -52.68 | -54.11 | -323.15 | -80.68 | -- | -- | -92.42 | -756.15 | -- | -2.42 | 1.87 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
Data as of Sep 20 2024. Currency figures normalised to OSE Immunotherapeutics SA's reporting currency: Euro EUR
2.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mandarine Gestion SAas of 29 Feb 2024 | 230.00k | 1.05% |
| Saint Olive Gestion SNCas of 29 Dec 2023 | 120.00k | 0.55% |
| Mayr Investment Managers GmbHas of 28 Jun 2024 | 106.90k | 0.49% |
| La Fran�aise Asset Management SASas of 30 May 2024 | 98.72k | 0.45% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 30.48k | 0.14% |
| Alphajet Fair Investors SASas of 10 Sep 2024 | 13.00k | 0.06% |
| Chaussier Gestion SAas of 28 Jun 2024 | 9.00k | 0.04% |
| Gestys SAas of 26 Jul 2024 | 4.00k | 0.02% |
| Friedland Gestion SASas of 31 May 2024 | 2.50k | 0.01% |
| BFT Investment Managers SAas of 31 Jul 2024 | 0.00 | 0.00% |
More ▼
Data from 28 Mar 2024 - 10 Sep 2024Source: FactSet Research Systems Inc.
